Source – Gilead
On July 20, a leading force in HIV innovation, announced its significant participation in the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Australia, and virtually from July 23-26, 2023. During the conference, Gilead will provide updates on its key initiatives and collaborations, while also presenting new scientific findings from its research and development endeavors. The comprehensive data presented at the event, along with Gilead-led symposia, exemplify the company’s pioneering approach to advancing HIV prevention, treatment, and cure strategies. This underscores Gilead’s commitment to forming global partnerships with communities in its unwavering dedication to ending the HIV epidemic worldwide.
“HIV will remain a global epidemic so long as people and communities do not have access to HIV care, services and innovative and life-saving medicines due to structural and social inequalities. At Gilead, our efforts at the global, national and local levels aim to reduce these disparities, with an emphasis on eliminating stigma and discrimination, ensuring equitable access to people-centered HIV care and services, and forging industry-leading partnerships that expand global access to our innovative and life-saving medicines. During IAS 2023, we look forward to sharing the latest from our ongoing health equity efforts and launching a new community-based initiative that seeks to change the future of the HIV epidemic.”
– Alex Kalomparis, Senior Vice President, Public Affairs, Gilead Sciences
At IAS 2023, Gilead will host two symposia to delve into the latest developments in policies and practical solutions worldwide, aimed at achieving more equitable access to HIV care and services.
